Tissue Plasminogen Activator (t-PA) Considered

This measure is to be reported for all patients aged 18 years and older undergoing active treatment for ischemic stroke for **each** hospital stay during the reporting period.

Measure description

Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke whose time from symptom onset to arrival is less than 3 hours who were considered for t-PA administration

What will you need to report for each hospital stay for patients under active treatment for ischemic stroke for this measure?

If you select this measure for reporting, you will report:

- The time of ischemic stroke symptom onset for each patient with a diagnosis of ischemic stroke:
 - Onset of less than three hours prior to arrival
 - Onset greater than or equal to 3 hours prior to arrival

If the time from symptom onset to arrival is less than three hours, you will then need to report:

 Whether or not you considered administration of t-PA for the patient (includes patients to whom t-PA was given or patients for whom reasons for not being a candidate for t-PA therapy are documented)

What if this process or outcome of care is not appropriate for your patient?

Some measures provide an opportunity for the physician or non-physician provider to document when a process or outcome of care is not appropriate for a given patient (also called performance exclusions). Because this measure is applicable to most if not all patients, there are no allowable performance exclusions.

Tissue Plasminogen Activator (t-PA) Considered

PQRI Data Collection Sheet

				/ /	🗆 Male 🛛 Female
Practice Medical Record Number (MRN)			Birth Date (mm/dd/yyyy)	Gender	
National Provider Identifier (NPI)			Date of Service		
Clinical Information				Billing Information	
Step 1 Is patient eligible for thi	s measure?				
		Yes	No	Code Required on Claim Form	
Patient is aged 18 years and older.				Verify date of birth on claim for	orm.
Patient has a diagnosis of ischemic stro	ke.			Refer to coding specifications document for list of applicable codes.	
There is a CPT E/M Service Code for th	is visit.				
If No is checked for any of the above, STOP. Do not report a CPT category II code.					
Step 2 Does patient also have the other requirements for this measure?					
		Yes	No	Code to be Reported on Line 24 (or Service Line 24 of Electron	
Is the time of symptom onset less than prior to arrival?	3 hours			If No (ie, symptom onset ≥ 3 h hospital), report only 1066F at	
				If Yes (ie, symptom onset < 3 hospital), report 1065F and p	
Step 3 Does patient meet the m	easure?				
Tissue Plasminogen Activator Administra	ation (t-PA)	Yes	No	Code to be Reported on Line 24 if <i>Yes</i> (or Service Line 24 of El	
Considered (includes patients to whom or patients for whom reasons for not be for t-PA therapy are documented)				4077F	
				If No is checked for the above, 4077F–8P (t-PA administration was not c otherwise specified.)	

Tissue Plasminogen Activator (t-PA) Considered

Coding Specifications

Codes required to document patient has ischemic stroke and a visit occurred:

An ICD-9 diagnosis code for ischemic stroke and a CPT E/M service code are required to identify patients to be included in this measure.

Ischemic stroke ICD-9 diagnosis codes

- 433.01, 433.11, 433.21, 433.31, 433.81, 433.91 (occlusion and stenosis of cerebral arteries),
- 434.01, 434.11, 434.91 (occlusion of cerebral arteries)

AND

CPT E/M service codes

- 99221, 99222, 99223 (initial inpatient),
- 99251, 99252, 99253, 99254, 99255 (inpatient consult),
- 99291 (critical care services)

Quality codes for this measure (at least one of the following for every eligible patient):

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate combination of codes.)

- *CPT II 1065F:* Ischemic stroke symptom onset of less than 3 hours prior to arrival
- *CPT II 1066F:* Ischemic stroke symptom onset greater than or equal to 3 hours prior to arrival
- *CPT II 4077F*: Documentation that tissue plasminogen activator (t-PA) administration was considered
- CPT II 4077F-8P: Tissue plasminogen activator (t-PA) administration was not considered, reason not otherwise specified

Physician Performance Measures (Measures) and related data specifications, developed by the American Medical Association (AMA) in collaboration with the Physician Consortium for Performance Improvement (the Consortium) and the National Committee for Quality Assurance (NCQA) pursuant to government sponsorship under subcontract 6205-05-054 with Mathematica Policy Research, Inc. under contract 500-00-0033 with Centers for Medicare & Medicaid Services.

These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2004-6 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[®]) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2007 American Medical Association

G codes and associated descriptions included in these Measure specifications are in the public domain.

PQRI 2008 Measure 34, Effective Date 01/17/2008

© 2004–6 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. CPT® copyright 2007 American Medical Association